Jane Street’s Amneal Pharmaceuticals AMRX Stock Holding History

Jane Street’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-71,300	Closed	-$886K	–	11449
2026 Q1	$886K	Buy	+71,300	New	+$957K	﹤0.01%	6781

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Jane Street's AMRX Position: Q1 2026 in Review

Jane Street sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 975,525 shares — an estimated $13.1M sold.

Jane Street first reported a position in AMRX in Q3 2018 and held it in 18 quarters. The position peaked at $12.3M in Q4 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Jane Street reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 975,525 Amneal Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
Jane Street first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 18 quarters.
Jane Street's Amneal Pharmaceuticals position peaked at $12.3M in Q4 2025.
317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.